Pneumococcal Vaccine Sequencing After an Outdated Polysaccharide-Only Regimen
A patient vaccinated under an outdated pneumococcal schedule needs her regimen brought current. The sequencing question has a clear answer; the product choice underneath it, current guideline in hand, genuinely does not.
M.T., a 68-year-old woman, retired last spring from four decades running the same small-town dry-cleaning business, and switched primary care physicians this year mainly because her old doctor's practice closed. She is otherwise healthy — no diabetes, no chronic lung or heart disease, a nonsmoker — and came in for a routine physical, where her new physician's chart review turned up a single dose of PPSV23 given five years ago, at age 63, under the guidance current at that time. No pneumococcal conjugate vaccine of any kind is on record.
Pneumococcal vaccine recommendations for adults have changed substantially since then. ACIP's updated guidance (Kobayashi et al., 2022, with the schedule further revised in 2024 to incorporate PCV21) now recommends that an adult who previously received PPSV23 alone receive a single dose of a conjugate vaccine at least one year later, rather than an additional PPSV23 dose. PCV15 remains a listed option, but since a prior PPSV23 dose already closes out that pathway, the practical choice for her is between the two higher-valency products, PCV20 and PCV21. The genuine complication isn't whether to close that gap — everyone in the room agrees she needs a conjugate dose now — it's which conjugate vaccine to actually give her. PCV20 and PCV21 differ meaningfully in which serotypes they cover: PCV20 retains several serotypes with declining adult prevalence, driven down by years of pediatric PCV program herd effects, while PCV21 was designed specifically around the serotype profile now causing the largest share of invasive pneumococcal disease in adults, deliberately dropping some of the pediatrically-relevant serotypes PCV20 still carries. Current ACIP guidance lists both as acceptable, guideline-concordant choices for exactly her situation — which means the sequencing question the visit was supposed to answer has a clear answer, and the product-choice question sitting directly underneath it does not.
Primary care, vaccine record reconciliation
The sequencing itself isn't in question — current ACIP guidance is direct about this: an adult who already received PPSV23 gets a single dose of PCV20 or PCV21 at least a year later, not another PPSV23 dose and not the PCV15-plus-PPSV23 sequence that predates her original vaccination. I'd give PCV20 today. It's what's on the shelf, it's fully guideline-concordant for exactly her history, and there's no clinical reason to make her wait for a referral to close a five-year-old gap.
I don't disagree that PCV20 is guideline-concordant. But I want to actually name the product question rather than let convenience answer it by default. PCV21 was built specifically around the serotypes causing the largest current share of invasive disease in adults her age, precisely because decades of pediatric PCV programs have already driven down several of the serotypes PCV20 still carries. For a healthy 68-year-old with no unusual exposure risk, that argument for PCV21 is real, not hypothetical — and it's worth naming before defaulting to whatever's already in the fridge.
Calling PCV20 the obvious choice because it's stocked here treats a genuine, guideline-acknowledged product question as if it had already been settled by the formulary, when it hasn't.
You're both arguing a question ACIP itself has deliberately left open — the 2024 update lists PCV20 and PCV21 as both acceptable for exactly this situation, in an immunocompetent adult without elevated risk, because the real-world effectiveness difference between them hasn't been established yet, not because one is clearly better. That makes this a genuinely underdetermined choice rather than a right-versus-wrong one. Given that, I don't think delaying protection to chase the marginally more theoretically-targeted product is worth it when the guideline doesn't pick a winner — give PCV20 today, and document plainly that this was a guideline-permitted choice between two reasonable options, not the only correct one.
Agreed: PCV20 given today, five years past her original PPSV23 dose and well clear of the one-year minimum interval, closing the outdated-regimen gap without further delay. The chart note documents explicitly that PCV21 was considered and is equally guideline-concordant, so a future clinician doesn't read today's choice as the only correct one.
Not agreed, and left on record rather than smoothed over: whether PCV21's more targeted current-day serotype coverage makes it the better product for a healthy adult in her situation specifically, or whether that distinction won't matter in practice until more real-world effectiveness data mature. The primary care physician would refer a similar future patient to PCV21 if the visit weren't time-sensitive; the pharmacist would default to whichever conjugate vaccine is actually on hand.